Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA5A | P35218 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4406050 | 0.79 | ALDH1A1 (0.44) | MAPK1ALDH1A1ALOX15KDM4E | |
| SCHEMBL7262937 | 0.79 | MAPK1 (0.32) | MAPK1ALDH1A1ALOX15 | |
| SCHEMBL5270913 | 0.79 | ESR1 (0.48) | ALDH1A1ALOX15 | |
| SCHEMBL979053 | 0.76 | ALDH1A1 (0.41) | CYP2A6ALDH1A1KDM4E | |
| SCHEMBL1534916 | 0.76 | — | — | |
| SCHEMBL2529902 | 0.75 | KIF11 (0.38) | MAPK1ALDH1A1ALOX15 | |
| SCHEMBL4283998 | 0.75 | CYP2A6 (0.42) | CYP2A6MAPK1ALDH1A1CA1CA2 | |
| SCHEMBL5454232 | 0.75 | CYP3A4 (0.42) | MAPK1ALDH1A1ALOX15KDM4E | |
| SCHEMBL15774676 | 0.75 | KIF11 (0.48) | CYP2A6ALDH1A1CA2CA9 | |
| SCHEMBL481494 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1362855-B1 | BETA-LACTAM COMPOUNDS, PROCESS FOR REPODUCING THE SAME AND SERUM CHOLESTEROL-LOWERING AGENTS CONTAINING THE SAME | KOTOBUKI PHARMACEUTICAL CO LTD (JP) | 2007-10-03 | — | — | EP | disclosed |
| US-7045515-B2 | β-lactam compounds process for reproducing the same and serum cholesterol-lowering agents containing the same | KOTOBUKI PHARMACEUTICAL CO., LTD. (JP) | 2006-05-16 | — | — | US | disclosed |
| US-20040063929-A1 | Beta-lactam compounds process for reproducing the same and serum cholesterol-lowering agents containing the same | KOTOBUKI PHARMACEUTICAL CO., LTD. (JP) | 2004-04-01 | — | — | US | disclosed |
| EP-1362855-A1 | BETA-LACTAM COMPOUNDS, PROCESS FOR REPODUCING THE SAME AND SERUM CHOLESTEROL-LOWERING AGENTS CONTAINING THE SAME | Kotobuki Pharmaceutical Co., Ltd. (JP) | 2003-11-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063929-A1 | Beta-lactam compounds process for reproducing the same and serum cholesterol-lowering agents containing the same | HMGCR, NCEH1, CETP | CYP2A6 327/4885MAPK1 3049/4885ALDH1A1 859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.